Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs
Alberto Rastrojo1, Raquel García-Hernández2, Paola Vargas2
1Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Universidad Autónoma de Madrid, Madrid, Spain.
Abstract:
Leishmaniasis is a serious medical issue in many countries around the World, but it remains largely neglected in terms of research investment for developing new control and treatment measures. No vaccines exist for human use, and the chemotherapeutic agents currently used are scanty. Furthermore, for some drugs, resistance and treatment failure are increasing to alarming levels. The aim of this work was to identify genomic and trancriptomic alterations associated with experimental resistance against the common drugs used against VL: trivalent antimony (SbIII, S line), amphotericin B (AmB, A line), miltefosine (MIL, M line) and paromomycin (PMM, P line). A total of 1006 differentially expressed transcripts were identified in the S line, 379 in the A line, 146 in the M line, and 129 in the P line. Also, changes in ploidy of chromosomes and amplification/deletion of particular regions were observed in the resistant lines regarding the parental one. A series of genes were identified as possible drivers of the resistance phenotype and were validated in both promastigotes and amastigotes from Leishmania donovani, Leishmania infantum and Leishmania major species. Remarkably, a deletion of the gene LinJ.36.2510 (coding for 24-sterol methyltransferase, SMT) was found to be associated with AmB-resistance in the A line. In the P line, a dramatic overexpression of the transcripts LinJ.27.T1940 and LinJ.27.T1950 that results from a massive amplification of the collinear genes was suggested as one of the mechanisms of PMM resistance. This conclusion was reinforced after transfection experiments in which significant PMM-resistance was generated in WT parasites over-expressing either gene LinJ.27.1940 (coding for a D-lactate dehydrogenase-like protein, D-LDH) or gene LinJ.27.1950 (coding for an aminotransferase of branched-chain amino acids, BCAT). This work allowed to identify new drivers, like SMT, the deletion of which being associated with resistance to AmB, and the tandem D-LDH-BCAT, the amplification of which being related to PMM resistance.
Insights
This study identifies genetic changes driving drug resistance in leishmaniasis, a neglected disease. Key findings include a gene deletion linked to amphotericin B resistance and gene amplification causing paromomycin resistance in Leishmania parasites.
Area of Science:
- Genomics and transcriptomics
- Parasitology
- Drug resistance mechanisms
Background:
- Leishmaniasis is a neglected tropical disease with limited treatment options.
- Increasing drug resistance and treatment failures necessitate new control strategies.
- Current research investment for leishmaniasis is insufficient.
Purpose of the Study:
- To identify genomic and transcriptomic alterations associated with experimental drug resistance in Leishmania.
- To validate potential drug resistance driver genes in different Leishmania species and life stages.
- To uncover novel molecular mechanisms underlying resistance to key antileishmanial drugs.
Main Methods:
- Generation of drug-resistant Leishmania lines (S, A, M, P lines).
- Differential gene expression analysis (transcriptomics) and whole-genome analysis (ploidy, copy number variations).
- Validation of candidate genes through transfection experiments in promastigotes and amastigotes.
Main Results:
- Identified 1006, 379, 146, and 129 differentially expressed transcripts in S, A, M, and P lines, respectively.
- Observed chromosomal ploidy changes and regional amplifications/deletions in resistant lines.
- Validated a 24-sterol methyltransferase (SMT) gene deletion associated with amphotericin B resistance and D-lactate dehydrogenase-like protein (D-LDH) and branched-chain amino acid aminotransferase (BCAT) gene amplification linked to paromomycin resistance.
Conclusions:
- Genomic and transcriptomic alterations are key drivers of drug resistance in Leishmania.
- SMT gene deletion is a novel mechanism conferring amphotericin B resistance.
- Amplification of the tandem D-LDH-BCAT genes is a significant mechanism for paromomycin resistance.
- Identified novel drug resistance targets for developing new therapeutic strategies against leishmaniasis.
More Related Videos
Related Concept Videos
Genomics
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Genome Size and the Evolution of New Genes
Altered States of Awareness
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
Alterations in Blood Pressure
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...


